142 related articles for article (PubMed ID: 3315283)
21. [Treatment of childhood acute lymphoblastic leukemia: efficacy of intermittent pulses of 6-mercaptopurine and methotrexate for maintenance chemotherapy, CCLSG-S811 (phase III study). Children's Cancer and Leukemia Study Group].
Koizumi S; Fujimoto T; Takeda T; Yatabe M; Katou K; Kaneko A; Sekine I; Takeshita T; Utsumi J; Kubota H
Rinsho Ketsueki; 1987 Aug; 28(8):1375-84. PubMed ID: 3323563
[No Abstract] [Full Text] [Related]
22. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
23. Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Dempsey SI; Bridges JM; Glasgow JF
Br J Cancer; 1980 Oct; 42(4):613-5. PubMed ID: 6934003
[No Abstract] [Full Text] [Related]
24. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children.
Borsi JD; Moe PJ
Cancer; 1987 Dec; 60(12):3020-4. PubMed ID: 3479231
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
Martelli N; Mathieu O; Margueritte G; Bozonnat MC; Daurès JP; Bressolle F; Hillaire-Buys D; Peyrière H
J Clin Pharm Ther; 2011 Apr; 36(2):237-45. PubMed ID: 21366654
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic management of remissions in acute lymphoblastic leukemia in children].
Armata J
Pol Tyg Lek; 1970 Nov; 25(44):1670-2. PubMed ID: 4921264
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics of small doses of methotrexate in patients with psoriasis.
Kamel RS; al-Hakiem MH; Rademaker M; Meyrick Thomas RH; Munro DD
Acta Derm Venereol; 1988; 68(3):267-70. PubMed ID: 2455425
[TBL] [Abstract][Full Text] [Related]
28. Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia?
Pinkerton CR; Glasgow JF; Bridges JM; Welshman SG
Br Med J (Clin Res Ed); 1981 Apr; 282(6272):1276-7. PubMed ID: 6784815
[No Abstract] [Full Text] [Related]
29. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen.
Bleyer WA; Coccia PF; Sather HN; Level C; Lukens J; Niebrugge DJ; Siegel S; Littman PS; Leikin SL; Miller DR
J Clin Oncol; 1983 May; 1(5):317-25. PubMed ID: 6366138
[TBL] [Abstract][Full Text] [Related]
30. Biopterin and neurotransmitter amine metabolism in children with acute lymphoblastic leukemia receiving methotrexate therapy.
Pinkerton CR; Smith I; Leeming RJ; Sarna G; Hyland K; Curzon G; Chessells JM
J Pediatr; 1986 Mar; 108(3):470-4. PubMed ID: 2419534
[TBL] [Abstract][Full Text] [Related]
31. New aspects of clinical and cellular pharmacodynamics of methotrexate with special emphasis on its role in the treatment of acute lymphoblastic leukemia in children.
Borsi JD; Moe PJ
Acta Paediatr Scand Suppl; 1987; 341():1-31. PubMed ID: 3328462
[No Abstract] [Full Text] [Related]
32. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
[TBL] [Abstract][Full Text] [Related]
34. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia.
Borsi JD; Revesz T; Schuler D
Cancer Chemother Pharmacol; 1987; 19(3):261-4. PubMed ID: 3472677
[TBL] [Abstract][Full Text] [Related]
35. Letter: Altered plasma pharmacokinetics of methotrexate administered intrathecally.
Jacobs SA; Bleyer WA; Chabner BA; Johns DG
Lancet; 1975 Feb; 1(7904):465-6. PubMed ID: 48664
[No Abstract] [Full Text] [Related]
36. Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.
Craft AW; Kay H; Lawson DN; McElwain TJ
Br Med J; 1977 Dec; 2(6101):1511-2. PubMed ID: 271033
[TBL] [Abstract][Full Text] [Related]
37. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
38. Renal function and methotrexate clearance in children with newly diagnosed leukemia.
Murry DJ; Synold TW; Pui CH; Rodman JH
Pharmacotherapy; 1995; 15(2):144-9. PubMed ID: 7624260
[TBL] [Abstract][Full Text] [Related]
39. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia.
Evans WE; Crom WR; Stewart CF; Bowman WP; Chen CH; Abromowitch M; Simone JV
Lancet; 1984 Feb; 1(8373):359-62. PubMed ID: 6141424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
